Quidel Receives FDA Clearance for Its New Solana(TM) Molecular System and Solana(TM) Molecular Assay for Diagnosis of Group a Streptococcal Infections
SAN DIEGO, CA -- (Marketwired) -- --
(NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market Quidel's new instrumented molecular system -- Solana -- and for the Solana Group A Strep Assay (Solana GAS Assay) for the rapid, qualitative detection of β-hemolytic, Group A Streptococcus (Streptococcus pyogenes) nucleic acids isolated from throat swab specimens from patients with signs and symptoms of pharyngitis, such as sore throat.
We appreciate your efforts to improve patient care, physician services, and laboratory efficiency. We know that you will appreciate the value that Quidel brings in delivering diagnostics that do not sacrifice accuracy or ease-of-use. Please explore this site for helpful resources and how you can contact us for further support.